Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer

CHIH-HSIN YANGZhou, CaicunCaicunZhouJänne, Pasi APasi AJänneRamalingam, Suresh SSuresh SRamalingamKim, Tae MinTae MinKimRiely, Gregory JGregory JRielySpira, Alexander IAlexander ISpiraPiotrowska, ZofiaZofiaPiotrowskaMekhail, TarekTarekMekhailGarcia Campelo, Maria RosarioMaria RosarioGarcia CampeloFelip, EnriquetaEnriquetaFelipBazhenova, LyudmilaLyudmilaBazhenovaJin, ShuShuJinKaur, ManmitManmitKaurDiderichsen, Paul MPaul MDiderichsenGupta, NeerajNeerajGuptaBunn, VeronicaVeronicaBunnLin, JianchangJianchangLinN Churchill, EricEricN ChurchillMehta, MinalMinalMehtaNguyen, DannyDannyNguyen2023-03-022023-03-022023-011473-7140https://scholars.lib.ntu.edu.tw/handle/123456789/628844Mobocertinib has demonstrated durable clinical benefit in platinum-pretreated patients (PPP) with epidermal growth factor receptor exon 20 insertion-positive non-small cell lung cancer (NSCLC).enCarcinoma; drug-related side effects and adverse reactions; epidermal growth factor receptor; non–small cell lung; patient safety; protein tyrosine kinases[SDGs]SDG3Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancerjournal article10.1080/14737140.2023.2157815365372042-s2.0-85145484810WOS:000904702000001https://api.elsevier.com/content/abstract/scopus_id/85145484810